BARCELONA, Spain--(BUSINESS WIRE)--INBRAIN Neuroelectronics, a brain-computer interface therapeutics (BCI-Tx) company pioneering graphene-based neural technologies, announced today the world’s first human procedure of its cortical interface in a patient undergoing brain tumor resection. INBRAIN’s BCI technology was able to differentiate between healthy and cancerous brain tissue with micrometer-scale precision..

西班牙巴塞罗那——（商业新闻短讯）——INBRAIN Neuroelectronics，一家脑-计算机接口治疗（BCI-Tx）公司，开创了基于石墨烯的神经技术，今天宣布了世界上第一个在接受脑肿瘤切除术的患者中进行皮质界面的人体手术。INBRAIN的脑机接口技术能够以微米级的精度区分健康和癌性脑组织。。

This milestone represents a significant advancement in demonstrating the ability of graphene-based BCI technology beyond decoding and translating brain signals, to become a reliable tool for use in precision surgery in diseases such as cancer, and in neurotechnology more broadly. The study was sponsored by the University of Manchester, and primarily funded by the European Commission’s Graphene Flagship project..

这一里程碑标志着在证明基于石墨烯的BCI技术超越解码和翻译大脑信号的能力方面取得了重大进展，成为用于癌症等疾病的精确手术以及更广泛的神经技术的可靠工具。这项研究由曼彻斯特大学赞助，主要由欧盟委员会的石墨烯旗舰项目资助。。

The clinical investigation study was conducted at Salford Royal Hospital, part of the Northern Care Alliance NHS Foundation Trust in Manchester, UK. The study was led by Chief Clinical Investigator Dr. David Coope, a neurosurgeon at the Manchester Centre for Clinical Neuroscience and Brain Tumours Theme Lead at the Geoffrey Jefferson Brain Research Centre, and Chief Scientific Investigator Kostas Kostarelos, Ph.D., Professor of Nanomedicine at The University of Manchester, the Catalan Institute of Nanoscience & Nanotechnology, and Co-Founder of INBRAIN..

这项临床研究是在英国曼彻斯特北部护理联盟NHS基金会信托基金会的一部分索尔福德皇家医院进行的。该研究由首席临床研究者大卫·库普博士领导，他是杰弗瑞·杰斐逊大脑研究中心曼彻斯特临床神经科学和脑肿瘤主题中心的神经外科医生，也是首席科学研究者科斯塔斯·科斯塔雷洛斯博士，曼彻斯特大学纳米医学教授，加泰罗尼亚纳米科学与纳米技术研究所，INBRAIN的联合创始人。。

“The world’s first human application of a graphene-based BCI highlights the transformative impact of graphene-based neural technologies in medicine. This clinical milestone opens a new era for BCI technology, paving the way for advancements in both neural decoding and its application as a therapeutic intervention,” said Carolina Aguilar, CEO and Co-Founder of INBRAIN Neuroelectronics..

INBRAIN Neuroelectronics首席执行官兼联合创始人卡罗莱纳·阿吉拉尔（Carolina Aguilar）表示：“世界上第一次人类应用基于石墨烯的脑机接口突出了基于石墨烯的神经技术在医学上的变革性影响。这一临床里程碑为脑机接口技术开辟了一个新时代，为神经解码及其作为治疗干预的应用铺平了道路。”。。

INBRAIN’s BCI platform leverages the exceptional properties of graphene, a material made of a single layer of carbon atoms. Despite being the thinnest known material to science, graphene is stronger than steel and possesses a unique combination of electronic and mechanical properties that make it ideal for neurotechnology innovation..

INBRAIN的BCI平台利用了石墨烯的特殊性能，石墨烯是一种由单层碳原子制成的材料。尽管石墨烯是科学界已知的最薄的材料，但它比钢更坚固，并且具有独特的电子和机械性能组合，使其成为神经技术创新的理想选择。。

“We are capturing brain activity in areas where traditional metals and materials struggle with signal fidelity. Graphene provides ultra-high density for sensing and stimulating, which is critical to conduct high precision resections while preserving the patient’s functional capacities, such as movement, language or cognition,” said Dr.

“我们正在捕捉传统金属和材料难以保持信号保真度的区域的大脑活动。石墨烯为传感和刺激提供超高密度，这对于进行高精度切除至关重要，同时保留患者的功能能力，如运动、语言或认知，”Dr。

David Coope, the neurosurgeon who performed the procedure..

David Coope，进行手术的神经外科医生。。

“After extensive engineering development and pre-clinical trials, INBRAIN’s first-in-human study will involve 8-10 patients, primarily to demonstrate the safety of graphene in direct contact with the human brain,” said Kostas Kostarelos, Ph.D., Co-Founder, INBRAIN Neuroelectronics. “The study will also aim to demonstrate graphene’s superiority over other materials in decoding brain functionality in both awake and asleep states.”.

INBRAIN Neuroelectronics联合创始人Kostas Kostarelos博士说：“经过广泛的工程开发和临床前试验，INBRAIN的首次人体研究将涉及8-10名患者，主要是为了证明石墨烯与人脑直接接触的安全性。”。“这项研究还旨在证明石墨烯在清醒和睡眠状态下解码大脑功能方面优于其他材料。”。

“The integration of graphene and AI with advanced semiconductor technology has allowed INBRAIN to pioneer a new generation of minimally-invasive BCI therapeutics designed for the personalized treatment of neurological disorders,” said Jose A. Garrido, Ph.D., Co-Founder and Chief Scientific Officer of INBRAIN and ICREA Professor at the Catalan Institute of Nanoscience and Nanotechnology..

INBRAIN联合创始人兼首席科学官、加泰罗尼亚纳米科学与技术研究所（Catalan Institute of Nanoscience and Nanotechnology）ICREA教授何塞·加里多（Jose a.Garrido）博士表示：“石墨烯和人工智能与先进半导体技术的结合，使INBRAIN开创了新一代微创脑机接口（BCI）疗法，旨在个性化治疗神经系统疾病。”。。

Professor Sir Kostya Novoselov, Ph.D., Nobel Laureate and Vision Board member of INBRAIN, who first isolated stable graphene at The University of Manchester in 2004, and now at the National University of Singapore, said: “Witnessing graphene's exceptional properties unlock new frontiers in medical technology is truly rewarding.

诺贝尔奖获得者、INBRAIN愿景委员会成员、博士Kostya Novoselov爵士于2004年在曼彻斯特大学（University of Manchester）和新加坡国立大学（National University of Singapore）首次分离出稳定的石墨烯，他说：“见证石墨烯的优异性能开启了医疗技术的新领域，真是值得的。

This breakthrough, a result of a decade-long development under the Graphene Flagship program, can now start to unravel its transformative societal impact.”.

这一突破是石墨烯旗舰计划十年发展的结果，现在可以开始揭示其变革性的社会影响。”。

The study is powered by INBRAIN’s graphene-based Intelligent Network Decoding & Modulation (BCI-Tx) Platform, which has received Breakthrough Device Designation for Parkinson’s disease from the U.S. Food & Drug Administration. INBRAIN’s BCI-Tx platform leverages graphene’s unique properties to deliver ultra-high signal resolution and adaptive neuroelectronic therapy, enabling real-time decoding of biomarkers and precise modulation of cortical and subcortical structures at the micrometer scale for neural network rebalancing..

这项研究由INBRAIN基于石墨烯的智能网络解码与调制（BCI-Tx）平台提供支持，该平台已获得美国食品和药物管理局针对帕金森氏病的突破性设备指定。INBRAIN的BCI-Tx平台利用石墨烯的独特特性提供超高信号分辨率和自适应神经电子疗法，从而能够实时解码生物标志物，并在微米尺度上精确调节皮层和皮层下结构，以实现神经网络的重新平衡。。

According to Carolina Aguilar, “INBRAIN is at the forefront of precision neurology, integrating BCI decoding with high-precision neuromodulation to restore function and alleviate symptoms, delivering continuous, personalized treatment to maximize benefits while minimizing side effects.”

根据Carolina Aguilar的说法，“INBRAIN处于精确神经病学的前沿，将BCI解码与高精度神经调节相结合，以恢复功能和缓解症状，提供持续的个性化治疗，最大限度地提高益处，同时最大程度地减少副作用。”

About INBRAIN Neuroelectronics

关于INBRAIN Neuroelectronics

INBRAIN Neuroelectronics is pioneering real-time precision neurology with the world’s first graphene-based brain-computer interface (BCI) therapeutics platform. Our technology combines precise BCI decoding with micrometric modulation to deliver adaptive, personalized treatments for conditions such as Parkinson’s disease, epilepsy, and stroke rehabilitation.

INBRAIN Neuroelectronics是世界上第一个基于石墨烯的脑-计算机接口（BCI）治疗平台的实时精确神经病学的先驱。我们的技术将精确的BCI解码与测微调制相结合，为帕金森氏病，癫痫和中风康复等疾病提供自适应，个性化的治疗。

By providing continuous real-time monitoring and autonomous therapy adjustments, our AI-driven platform maximizes therapeutic outcomes while minimizing side effects. Through strategic collaborations, including with Merck KGAa and our subsidiary INNERVIA Bioelectronics, we are extending our innovative solutions to peripheral nerve and systemic disease applications, unlocking the potential of neurotechnology and bioelectronics.

。通过战略合作，包括与默克KGAa和我们的子公司INNERVIA Bioelectronics的合作，我们正在将创新解决方案扩展到周围神经和全身性疾病的应用，释放神经技术和生物电子学的潜力。

For more information, visit www.inbrain-neuroelectronics.com and follow us on LinkedIn..

有关更多信息，请访问www.inbrain-neuroelectronics.com并在LinkedIn上关注我们。。

About Northern Care Alliance (NCA)

关于北方护理联盟（NCA）

Northern Care Alliance NHS Foundation Trust provides hospital and community healthcare services in Salford, Oldham, Bury and Rochdale. Our dedicated team of around 20,000 staff delivers high standards of care and experience excellence to over one million people across Greater Manchester and beyond, working together to save lives and improve lives.

北方护理联盟NHS基金会信托基金会在索尔福德、奥尔德姆、伯里和罗奇代尔提供医院和社区保健服务。我们拥有约20000名员工的敬业团队为大曼彻斯特及其他地区的100多万人提供高标准的护理和卓越体验，共同努力挽救生命和改善生活。

More information about the NCA can be found at www.northerncarealliance.nhs.uk.

有关NCA的更多信息，请访问www.northerncarealliance.nhs.uk。

About The University of Manchester

曼彻斯特大学简介

The University of Manchester is recognised globally for its pioneering research, outstanding teaching and learning, and commitment to social responsibility. The Russell Group institution is ranked the 6th best university in the UK and 38th in the world (Academic Ranking of World Universities). A truly international university, its community includes more than 44,000 students, 12,000 staff, and 500,000 alumni from 190 countries.

。罗素集团学院（RussellGroup Institute）被评为英国第六大最佳大学和世界第38名（世界大学学术排名）。作为一所真正的国际大学，它的社区包括来自190个国家的44000多名学生、12000名员工和500000名校友。

Together, they are tackling the world’s biggest challenges – the University’s social and environmental impact is ranked in the top ten globally (Times Higher Education Impact Rankings). The University is a powerhouse of research and discovery; 25 Nobel laureates are among its former staff and students; and it was ranked fifth for research power – the quality and scale of research and impact – in the UK government’s Research Excellence Framework (REF) 2021.

他们共同应对世界上最大的挑战——大学的社会和环境影响位列全球前十（泰晤士报高等教育影响排名）。这所大学是研究和发现的发电站；25位诺贝尔奖获得者是其前员工和学生；在英国政府2021年的卓越研究框架（REF）中，它在研究能力（研究的质量和规模以及影响力）方面排名第五。

The institution is the most popular in the UK for undergraduate applications (UCAS 2021 cycle), and it is the it is the most targeted university by the UK’s leading employers (The Graduate Market, 2023)..

该学院是英国最受欢迎的本科申请（UCAS 2021周期），也是英国主要雇主最有针对性的大学（毕业生市场，2023年）。。